ZBH · NYSE · STOCK
Zimmer Biomet (ZBH) Stock Analysis
$89.05
52W $79.12 – $106.88
62/100
$17.25B
21.6
0.48
Is ZBH Bullish or Bearish?
Bullish.
Innellis AI committee rates Zimmer Biomet (ZBH) Buy with a composite score of 62/100
, based on 5 analysts with 80% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +12.52 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -7.48 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Value Analyst sees a compelling case — price-to-book of 1.4x is a discount to asset value. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
62/100
Agreement
80%
Analysts
5
Conviction
High
Sector Rank
Top 18%
of 192 Healthcare peers
Value Analyst
bullish
70
/ 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
+ Price-to-book of 1.4x is a discount to asset value
Growth Analyst
bullish
68
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
61
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 61.8 to 62.5.
- Conviction changed from moderate to high.
- Committee agreement increased sharply from 60% to 80%.
- Analyst(s) changed stance: News Analyst.
Analyst-level changes:
- News Analyst: stance neutral->bullish; score 58->61 (+3).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
40.7
Neutral
MACD Histogram
-0.122
Bearish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Hh Hl
Support
$85.83
Resistance
$95.31
Bollinger %B
0.28
Inside Bands
Price vs Moving Averages
EMA 9
$89.68
Below
EMA 21
$91.53
Below
EMA 50
$93.16
Below
EMA 200
$92.59
Below
Fundamental Analysis
Valuation
58
Growth
66
Profitability
51
Financial Health
85
Cash Flow
70
Valuation
P/E Ratio
21.6×
P/B Ratio
1.36×
PEG Ratio
88.92
Dividend Yield
1.08%
52W High
$106.88
52W Low
$79.12
Quality & Growth
ROE
555.4%
ROA
305.4%
Gross Margin
6987.4%
Operating Margin
1572.9%
Revenue Growth YoY
—
Debt / Equity
0.59
AI Fundamental Assessment
P/E ratio of 21.6 (inexpensive relative to a 15-40x range); Price-to-book of 1.4x; PEG ratio of 88.9 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 5.6%; Return on assets of 3.1%; Net margin of 9.5%; Gross margin of 69.9%; Current ratio of 1.69 (healthy short-term liquidity); Debt-to-equity of 0.59; Free cash flow per share is positive (9.52); Most recent quarter beat estimates by 2.0%; 5 consecutive earnings beats; EPS growth accelerating (-13.6% -> -1.0% QoQ); Average YoY EPS growth of 0.0%; Analyst estimates falling over recent quarters
Get the Full ZBH Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →